Recommended Dosing for Saccharomyces boulardii
For adults and children ≥12 years, the recommended dose is 250-500 mg twice daily (equivalent to approximately 5-10 billion CFU twice daily), while children under 12 years require 250 mg twice daily (5 billion CFU twice daily), with treatment typically lasting 5 days for acute diarrhea or continuing throughout antibiotic therapy plus 14 days afterward for antibiotic-associated diarrhea prevention. 1, 2, 3
Adult Dosing
Standard Therapeutic Dose
- 250-500 mg twice daily (5-10 billion CFU/day total) is the evidence-based dose for most indications 1, 2, 4
- Higher doses (≥10^10 CFU/day) demonstrate superior efficacy across multiple conditions 1, 5
- One FDA-labeled formulation recommends 10 drops up to 3 times daily for adults ≥12 years, though this appears to be a homeopathic preparation with different dosing 6
Specific Clinical Scenarios
For Clostridioides difficile infection (adjunct therapy):
- 1 gram daily (3×10^10 CFU/day) as adjunct to standard antibiotic therapy 1
- This higher dose increases cessation of diarrhea (RR 1.33) and decreases recurrence (RR 0.59) 1
For antibiotic-associated diarrhea prevention:
- 250-500 mg twice daily starting with the first antibiotic dose and continuing until 14 days after the last antibiotic dose 1, 3, 7, 8
- The American Gastroenterological Association specifically recommends S. boulardii as a single-strain option for preventing C. difficile infection during antibiotic therapy 1
- Reduces antibiotic-associated diarrhea risk by approximately 50% 1, 5
For traveler's diarrhea prevention:
- 250-1000 mg daily with dose-dependent efficacy (higher doses more effective) 9
- Particularly effective in North Africa and Near East regions 9
Pediatric Dosing
Children Under 12 Years
- 250 mg twice daily (5 billion CFU twice daily) for 5 days is the standard pediatric dose 2, 4, 3
- This dose significantly reduces diarrhea duration by approximately 28.9 hours in children with acute gastroenteritis 1
- FDA labeling recommends consulting a physician for children under 12 years 6
Age-Specific Considerations
- Infants 3-36 months: 5 billion CFU twice daily for 5 days demonstrated significant efficacy in reducing diarrhea duration (65.8 vs 95.3 hours in placebo) 2
- Children 6 months-14 years: 250 mg twice daily during antibiotic treatment reduced antibiotic-associated diarrhea from 23% to 8% 3
Duration of Treatment
Acute Diarrhea
- 5 days is the standard treatment duration for acute gastroenteritis 1, 5, 2, 4
- Recovery typically occurs within 3-4 days with S. boulardii versus 4-5 days with placebo 2, 4
Antibiotic-Associated Diarrhea Prevention
- Continue throughout entire antibiotic course plus 14 days afterward 7, 8
- Initiate within 48 hours of starting antibiotics for optimal efficacy 7
Critical Implementation Points
Timing Considerations
- Administer 30 minutes before or after meals per FDA labeling 6
- For antibiotic-associated diarrhea prevention, start S. boulardii upon initiation of antibiotic treatment or within 48 hours 7
Common Pitfall to Avoid
- Do NOT use probiotics (including S. boulardii) for acute infectious gastroenteritis in children in North America, as the American Gastroenterological Association recommends against this based on moderate-quality evidence showing no benefit 1, 5
- This recommendation is specific to the North American context; European guidelines differ 1
Safety Considerations
Contraindications and Cautions
- Avoid entirely in: immunocompromised patients, premature neonates, patients with central venous catheters, critically ill patients, cardiac valvular disease, and short-gut syndrome 1, 5
- Generally well-tolerated with no significant adverse events reported in clinical trials 2, 4, 3
Special Populations
- Pregnancy and breastfeeding: Consult healthcare professional before use 6
- No specific dose adjustments documented, but medical supervision recommended 6
Strain-Specific Note
The evidence specifically supports Saccharomyces boulardii CNCM I-745 and CNCM I-3799 strains 1, 2, 7. Effects are strain-specific, so products should clearly identify the complete strain designation to ensure you're using an evidence-based formulation 10.